title: [Molecular medicine and treatment of tuberculosis].
authors.forename: M I
authors.initials: MI
authors.lastname: Perel'man
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Khomiakov
authors.forename: V I
authors.initials: VI
authors.lastname: Kiselev
authors.forename: E S
authors.initials: ES
authors.lastname: Severin
authors.forename: M A
authors.initials: MA
authors.lastname: Pal'tsev
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000904:Antibiotics, Antitubercular / Q000494:pharmacology* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology; D005260:Female; D005818:Genetic Engineering; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics*; D011110:Polymorphism, Genetic; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D014376:Tuberculosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control
chemical_list: D000276:Adjuvants, Immunologic; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D001500:BCG Vaccine; D007538:Isoniazid; D012293:Rifampin